Intravitreal anti-vascular endothelial growth factor (VEGF) drugs have revolutionized the
treatment of neovascular age-related macular degeneration (NVAMD). However, many …

As a progressive chronic disease, age-related macular degeneration (AMD) is the leading
cause of irreversible vision impairment worldwide. Experimental and clinical evidence has …

The introduction of anti-vascular endothelial growth factor (anti-VEGF) has made significant
impact on the reduction of the visual loss due to neovascular age-related macular …

Clinical efficacy of intravitreal anti-VEGF drugs has been widely demonstrated in several
angiogenesis-driven eye diseases including diabetic macular edema and the neovascular …

The mammalian retina displays no intrinsic regenerative capacities, therefore retinal
degenerative diseases such as age-related macular degeneration (AMD) or retinitis …

Age-related macular degeneration (AMD) affects the retinal pigment epithelium (RPE), a cell
monolayer essential for photoreceptor survival, and is the leading cause of vision loss in the …

Roughly ten years ago the FDA approved most of the presently used anti-VEGF drugs for the
treatment of neovascular AMD and other eye pathologies characterized by ocular …

The aim of the present study was to determine the efficacy and safety of intravitreal
brolucizumab therapy for neovascular age-related macular degeneration (AMD) in the real …

Diabetic retinopathy is a major cause of ocular complications in patients with type 1 and type
2 diabetes in developed countries. Due to the continued increase in the number of people …

Purpose To evaluate the association of baseline characteristics and early visual acuity (VA)
response with visual outcomes at years 1 or 2 in the Comparison of Age-Related Macular …